CEFTIN
LOE ApproachingNDAORALTABLET
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEFTIN is an oral cephalosporin antibiotic approved in 1987 for bacterial infections. The drug is a small-molecule beta-lactam that inhibits bacterial cell wall synthesis. It is used across multiple infection types where oral cephalosporin therapy is indicated.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100) suggests contraction phase; brand team focus shifts to defending market share against generics and newer agents.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CEFTIN offers limited career growth due to LOE-approaching lifecycle and zero linked job openings. Roles available are defensive in nature, focused on generic transition, market share retention, and regulatory compliance rather than expansion or innovation.
Brand ManagerCommercial Operations Manager
Worked on CEFTIN at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.